CD8A and melanoma: To assess the induction of primary SARS-CoV-2-specific CD8+ responses in unexposed healthy individuals, we exploited an in vitro system initially developed to prime naive T cells specific for the HLA-A2-restricted melanoma epitope EV10 in melanoma-naive donors (Figure 1A).